MedTrace Logo

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

NCT05018273 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-12-03

No results posted yet for this study

Summary

A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).

Conditions

  • Solid Tumors, Adult

Interventions

BIOLOGICAL

VB10.NEO

The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Vaccibody AS

    collaborator INDUSTRY

  • Nykode Therapeutics ASA

    lead INDUSTRY

Principal Investigators

  • Siri Torhaug, MD · Nykode Therapeutics ASA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2024-10-09
Completion
2024-10-09
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05018273 on ClinicalTrials.gov